What is Geneius Biotechnology's T-cell therapy?

Geneius Biotechnology develops autologous, adoptive T-cell therapies that re-educate a patient's natural T cells to attack multiple tumor-specific antigens that the immune system had previously overlooked. This is done through the company's SMAR-T™ platform without genetic engineering.

What clinical results has Geneius Biotechnology achieved?

An academic-sponsored proof-of-concept study using the same T cells produced by Geneius showed a 70% Overall Response Rate (ORR) and a 50% Complete Response (CR) rate, with complete remissions sustained at 5 years for half of those patients — and without significant toxicities.

How does Geneius T-cell therapy compare to CAR-T?

Geneius's natural T-cell therapy costs approximately 1/8th of CAR-T therapy, can be administered by community oncologists, causes only mild flu-like symptoms as side effects, and has shown efficacy in solid tumors — an area where CAR-T has not demonstrated clinical effectiveness.

What is the SMAR-T™ manufacturing process?

SMAR-T™ is Geneius Biotechnology's GMP manufacturing process. From 100 ml of a patient's blood, peripheral blood mononuclear cells (PBMCs) are collected and pulsed with antigenic peptides to generate 4 billion cells. These T cells are grown in a proprietary cytokine cocktail over 4 weeks until they reach the quantity and specificity needed for infusion.

Home | Geneius

Revolutionizing Cancer Care

Next generation T-cell immunotherapy

Personalized Immunotherapy

Re-educating the patient's immune system

Standardized Manufacturing

Keeping costs at insurance re-imbursable rates

Immunotherapy · Oncology

Advancing T-cell therapies
against cancer

GENEIUS is focused on the development & commercialization of innovative autologous, adoptive T-cell therapies, which offer a more robust immune response to cancer compared to current approaches.

Treating All Cancers where the patients live successfully and affordably, while maintaining their normal quality of life before, during, and after treatment.

Geneius' approach can be delivered in any patient's community at reimbursable rates — allowing patients to keep living their normal lives.

Geneius revolutionizes cancer care by harnessing the power of each patient's own immune system to target the mutations driving their cancer.

Reasonable Cost

Cost is reasonable at 1/8th that of CAR-T .

Accessibility

Community oncologists can provide this treatment. The physician does not lose the revenue from the patient as with other protocols whose severe side effects require transfer to a major cancer center.

Consistency

For 90% of cancer patients , we meet our FDA release criteria when manufacturing T cells from a patient's blood draw. We expect to validate that T cells manufactured by our improved commercial process will be as effective as those in academic studies — giving us real potential to treat a far higher percent of patients than PD-1s like Keytruda or Opdivo.

Advancing T-cell therapies against cancer

Reasonable Cost

Accessibility

Consistency

Advancing T-cell therapies
against cancer